Morphotek develops and manufactures therapeutic antibodies for the treatment of cancer, inflammation, and infectious disease.

Morphotek, Inc., is a clinical-stage biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.

Industry: Health
Status: Alumni

Contact Information

www.morphotek.com

info@morphotek.com

Nicholas Nicolaides

CEO and Co-Founder

Luigi Grasso

Co-Founder and CSO

Rod Dausch

CFO